Navigation Links
Pinnacle Biologics and INTERmedic Medical Devices announce strategic manufacturing and distribution agreement for cancer laser technology

BANNOCKBURN, Ill., June 26, 2012 /PRNewswire/ -- Pinnacle Biologics, Inc., a bio-pharmaceutical technology company developing and manufacturing novel therapies for oncology and rare diseases and European-based INTERmedic, a medical laser and light technology company, announced a global manufacturing and distribution agreement of INTERmedic's latest photodynamic therapy (PDT) laser for exclusive use with Pinnacle's PHOTOFRIN ® (porfimer sodium) for injection. 

PDT is a two-step process, which uses a photosensitizing drug activated inside the body by laser light to kill cells. The agreement creates a customized PDT application combining PHOTOFRIN, a photoactivated agent, with INTERmedic's newest endoscopic laser delivery device. The device is already approved in Europe. Pinnacle anticipates registration in the United States and other global markets within the next 12-18 months.

"PDT is an impactful, yet under utilized treatment strategy," said Guillermo Herrera, Pinnacle Executive Chairman and CEO. "Pinnacle's goal is to support worldwide development of PDT with PHOTOFRIN in a way that elevates awareness and use among physicians and alerts patients to this cancer treatment option."

Pinnacle acquired PHOTOFRIN in March 2011 with the goal of solidifying its corporate presence and global leadership in the photodynamic therapy field by normalizing product supply, expanding availability and education among current customers, and targeting areas of unmet medical need as new indications for use of PDT.

Pinnacle is working with regulators, top academic institutions and opinion leaders to accelerate product development in areas where the product has shown evidence of safety and efficacy for the benefit of patients affected by rare and devastating diseases.

"PDT for cancer is an advanced therapeutic approach that needs to be expanded and further developed," said Patrick Ross, MD, Ph.D., professor of clinical surgery and Chairman of Pinnacle's Scientific Advisory Board. "Pinnacle's strategic development of PDT with PHOTOFRIN and its commitment to extending its indications and applications are clear signals we can achieve those goals."

About Photodynamic therapy (PDT) and PHOTOFRIN

Photodynamic therapy with PHOTOFRIN is a two-stage process requiring administration of both drug and light. The first stage of PDT is the intravenous injection of PHOTOFRIN. The second stage of therapy uses illumination with non-burning laser light 40–50 hours following injection with PHOTOFRIN. When injected, PHOTOFRIN is attracted to certain tissues, especially cancer cells. Tumor destruction results from biochemical reactions, not heat.  Tumor selectivity occurs through a combination of preferential retention of PHOTOFRIN by the tumor and selective delivery of light to the tumor site.

PHOTOFRIN is FDA approved for the treatment of non-small cell lung cancer (NSCLC) and esophageal cancer. The product is available in the USA, several major European countries, Japan, several Latin American and Southeast Asian markets. PHOTOFRIN also is approved for high-grade dysplasia (HGD) in Barrett's esophagus (BE) in North America. It also has Orphan Drug Designation (ODD) for cholangio-carcinoma and as adjuvant therapy to surgery for the treatment of malignant pleural mesothelioma.

For additional information about PHOTOFRIN, please see full prescribing information available at

About Pinnacle

Pinnacle Biologics, Inc. is a privately held bio-pharmaceutical company specializing in revitalizing healthcare therapies to expand therapeutic potential and maximize favorable patient outcomes. The company is headquartered in Bannockburn, Illinois. Its European subsidiary, Pinnacle BiologicsBV, is headquartered in Amsterdam and is the holder of the European Marketing Authorizations for Pinnacle products.

About INTERmedic

INTERmedic is a dynamic laser & light technology company in a flux of constant expansion. The company is dedicated to the development, production and marketing of innovative laser and highly advanced pulsed light systems as well as other new technologies covering a wide range of medical applications. INTERmedic is one of Europe's leading laser manufacturers and marketers.

INTERmedic offers attending physicians innovative, patient-friendly solutions, well adapted to use by the applicant in aesthetics, dermatology, vascular medicine, plastic and general surgery. The company's solid standing in vascular surgery, with the minimally invasive method to treat varicose veins, guarantees its position as the world's number one in endovenous laser treatments.

SOURCE Pinnacle Biologics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. CMC Biologics Achieves Successful Pre-Approval European GMP Inspection by MHRA for Commercial Manufacturing
2. Chinese Compulsory Immunization Program for Livestock Creates Massive Opportunity for Animal Vaccines and Biologics Developers
3. Avaxia Biologics Announces Appointment of Michael D. Rivard as VP Corporate Development
4. CSL Behring Announces FDA Filing of Biologics License Application for 4-Factor PCC for Urgent Reversal of Vitamin K Antagonist Anticoagulant Therapy
5. Avaxia Biologics is Awarded U.S. Patent for Method to Treat Radiation Damage to the Digestive Tract and Mucositis Caused by Radiation
6. Synthetic Biologics Appoints Carol Reed, M.D., as Senior Vice President of Clinical & Regulatory Affairs
7. Althea Technologies Appoints Dr. Kristin DeFife, Director, Biologics Manufacturing And Jack Wright, VP, Sales and Marketing
8. ICON Medical Imaging Selects AG Mednet to Give Clinical Trial Sponsors Zero-Delay Efficiency and Faster Decision-Making Results
9. US Disposable Medical Supplies Market
10. Accuray and Erasmus Medical Center Sign Master Research and Collaboration Agreement
11. Collagen Matrix Celebrates 15th Anniversary in the Medical Device Business
Post Your Comments:
(Date:11/26/2015)... North Carolina , 26 november 2015 ... Inc. (AAIPharma/CML) kondigt de geplande investering aan ... uitbreiding van de laboratoria en het mondiale ... . De uitbreiding zal resulteren in extra ... wordt voldaan aan de groeiende behoeften van ...
(Date:11/26/2015)... 3D bioprinting market is expected ... new report by Grand View Research Inc. Rising prevalence of ... kidney transplantation is expected to boost the market growth, as ... transplantation. --> 3D bioprinting market is expected ... new report by Grand View Research Inc. Rising prevalence of ...
(Date:11/26/2015)... --> ... att använda SyMRI för att hitta optimal ... med multipel skleros (MS) eller hjärntumörmetastaser och ... för att kunna använda SyMRI Research Edition ... kan man generera flera konstrastbilder från en ...
Breaking Medicine Technology:
(Date:11/26/2015)... (PRWEB) , ... November 26, 2015 , ... Jobs in ... by healthcare professionals and offered by healthcare staffing agency Aureus Medical Group . ... the month of October 2015 among those searching for healthcare jobs through the company’s ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... opinion process, participated in the 61st annual Employee Benefits Conference. The Employee Benefits ... place Sunday, November 8th through Wednesday, November 11th, 2015. The conference was held ...
(Date:11/26/2015)... ... November 26, 2015 , ... ... and wellness consultation, has collaborated with Women’s Web – an online resource ... on topics on mental and emotional well-being relationship, life balance, stress, professional ...
(Date:11/25/2015)... Ill. (PRWEB) , ... November 25, 2015 , ... ... and potentially more aggressive than those found on mammography, according to a study ... findings of additional cancers not seen on mammography may necessitate a change in ...
(Date:11/25/2015)... ... November 25, 2015 , ... The holiday season is ... pleasing the palates of attendees is of the utmost importance. Whether you are ... get-together, give these recipes a try this holiday season. , Turkey Croquettes , ...
Breaking Medicine News(10 mins):